trending Market Intelligence /marketintelligence/en/news-insights/trending/8fxjflk_aerfmb_-zmr2_w2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Kala Pharmaceuticals seeks FDA approval for dry eye disease therapy

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Kala Pharmaceuticals seeks FDA approval for dry eye disease therapy

Kala Pharmaceuticals Inc. is seeking approval from the U.S. Food and Drug Administration for its medicine KPI-121 0.25%, which could become the first approved therapy for treating symptoms of dry eye disease.

Dry eye disease occurs when the tears are not able to provide adequate lubrication for the eyes. The symptoms include irritation, redness, discharge, fatigued eyes and even blurred vision. The Waltham, Mass.-based company said that about 33 million Americans have dry eye disease and about 90% of these patients have flares associated with the condition.

The company said its topical treatment KPI-121 0.25% could offer a favorable management option for these dry eye flares and other dry eye-associated conditions.

Kala submitted an application to the FDA for the drug's approval based on positive data from three trials, including one phase 2 and two phase 3 trials in 2,000 patients with dry eye diseases, according to an Oct. 16 press release. The company said a third phase 3 trial is underway, dubbed Stride 3, to evaluate KPI-121 0.25% for temporary relief of the symptoms of dry eye disease.

In August, the biopharmaceutical company secured FDA approval for its drug Inveltys as a treatment for pain after eye surgery.